Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
El Bono 3 del Fondo para pymes 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se reabrirá el lunes 2 de junio de 2025. Puede consultar más información aquí.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
126
resultados
Última actualización
14/06/2025 [08:40:00]
Resumen de: WO2025122530A1
The disclosure relates to compositions and methods for, inter alia, altering, e.g., enhancing, the level of GBA1 protein via delivery using an adeno-associated viral (AAV) capsid variant. The compositions and methods of the present disclosure are useful, inter alia, for the treatment of subjects who have, have been diagnosed with having, or are at risk of having a GBA1-related disorder, e.g., Parkinson's Disease (PD), Gaucher Disease (GD), Parkinson's Disease Dementia (PDD), Dementia with Lewy Bodies (DLB), or Lewy Body Dementia (LBD).
Resumen de: WO2025120587A1
A composition for preventing and treating neurodegenerative diseases and cognitive disorders is provided, comprising a mixture of active ingredients, including choline bitartrate, Cordyceps, Hericium, and Bacopa.
Resumen de: AU2023403257A1
Provided herein are methods for treating Alzheimer' s disease using a combination of tramiprosate, a tramiprosate prodrug or an active tramiprosate metabolite with at least one amyloid plaque clearing agent.
Resumen de: AU2023402123A1
The compositions of the present invention contain a novel aldehyde dehydrogenase derived from a novel mutant yeast, that improve memory and cognitive function. The present invention relates to a food and pharmaceutical composition for preventing Alzheimer's disease and Huntington disease by reducing the accumulation of lesional proteins in brain tissue. The food or pharmaceutical compositions of the present invention contain a lysate of any one or a mixture thereof selected from the group consisting of Saccharomyces cerevisiae, KCTC13925BP, KCTC14122BP, KCTC14123BP, KCTC14983BP, KCTC14984BP and KCTC14985BP.
Resumen de: US2025186363A1
Pharmaceutical compositions and methods for treating and/or preventing and/or control of Parkinson's Disease and/or related symptoms in a patient.
Resumen de: WO2025122565A1
Methods and compositions for treating neurodegenerative disorders comprising crRNA molecules targeting exon1a and/or intron 1 of C9ORF72 and a Cas13 protein or a polynucleotide encoding a Cas13 are provided.
Resumen de: US2025186382A1
The present disclosure relates to compositions of levodopa 4′-monophosphate and carbidopa 4′-monophosphate having a weight by weight ratio of about 20:1 and methods of treating Parkinson's disease and associated conditions by subcutaneous administration of such compositions.
Resumen de: US2025186567A1
The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (Aβ, Abeta) peptide, a tau peptide, and an alpha-synuclein peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of Aβ and tau and an alpha-synuclein, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds and an alpha-synuclein synucleinopathies in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and amyloid-beta and an alpha-synuclein accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (Aβ) peptide and a tau peptide and an alpha-synuclein peptide.
Resumen de: US2025186439A1
Provided herein are novel therapeutic applications of Pyk2 (PTK2B) inhibitors to treat low bone mineral density and/or osteoporosis and to treat, prevent, or delay the progression of neurodegenerative disorders such as Alzheimer's disease.
Resumen de: US2025188158A1
A method of treating, preventing or ameliorating Parkinson's disease or the symptoms thereof, including motor and cognitive function-related symptoms, through the administration of an anti-synuclein antibody (e.g., Prasinezumab). Methods include maintaining motor function or cognitive function, and slowing decline in motor function and cognitive in a subject having Parkinson's disease or at risk of Parkinson's disease.
Resumen de: WO2025122121A2
The present invention relates to a method (100) of synthesizing novel multi¬ effective urea/thiourea compounds which provide simultaneous inhibition of cholinesterase (AChE) and monoamine oxidase (MAO) enzymes known to play roles in Alzheimer's disease (AD); can interact with Ap peptides and/or P amyloid plaque; provide neuroprotective effect by reducing oxidative damage; and to the synthesized compounds and the biological activities they exhibit.
Resumen de: WO2025122626A1
Hydrogen-bonded framework nanoparticles comprising a chemiluminescent compound (e.g., L-012) are provided and can be used, e.g., for sono-optogenetic treatment of neurodegenerative diseases such as Parkinson's disease. Related in vivo and therapeutic methods are also provided.
Resumen de: EP4566629A2
The present invention refers to a composition comprising human albumin at a concentration between 5 % (w/v) and 25 % (w/v) for the treatment of mild and moderate Alzheimer's Disease (AD) by low-volume plasma exchange (LVPE).
Resumen de: WO2024153712A1
The present invention relates to a liposomal composition for use in a method of treating Parkinson's disease. The liposomal composition comprises sphingomyelin in a lipid bilayer and a therapeutically ef fective amount of monosialotetrahexosylganglioside (GM1), wherein a therapeutically ef fective dose of said liposomal composition is administered at most every 4 days in a primary mode of administration with at least 3 days between each administration; preferably at most every 6 days in a primary mode of administration with at least 5 days between each administration; most preferably at most every 7 days in a primary mode of administration with at least 6 days between each administration.
Resumen de: AU2023319981A1
The invention provides methods of treating patients with Parkinson's disease (PD) associated with wild-type LRRK2. The invention recognizes that analysis of biomarkers in such patients allows identification of those patients who will respond to LRRK2 inhibitors. Thus, the invention provides methods of identifying PD patients who will respond to LRRK2 inhibitors and methods of treating such patients.
Resumen de: US2025177351A1
The present invention is directed to methods of treating Alzheimer's disease in a subject in need thereof. Also disclosed are methods of identifying novel compounds that may be useful in the treatment and prevention of Alzheimer's disease. Also disclosed are methods of determining the Alzheimer's disease status of a subject.
Resumen de: WO2025117721A1
The present disclosure provides products and methods for facilitating brain lipid transport in a subject. In some aspects the products are useful for slowing the progression of or preventing the development of Alzheimer's Disease or for treating Alzheimer's disease. The products include reconstituted lipoprotein particles (rLPs). Libraries and screening of libraries to identify additional rLPs are also disclosed.
Resumen de: WO2025113506A1
The present invention relates to the field of biomedicine. Provided are a marker that can be used for early diagnosis of Alzheimer's disease, and the use thereof. Specifically provided is a marker for early diagnosis of Alzheimer's disease. The marker is a Maf1 gene or the protein thereof. High expression of the Maf1 gene or the protein thereof in neuronal cells indicates that a subject is at high risk of developing Alzheimer's disease. The method provides a new diagnostic and therapeutic target for AD.
Resumen de: US2025177292A1
The present invention provides a method for treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of a composition comprising carbidopa and levopoda, or pharmaceutically acceptable salts thereof, and concomitant oral administration of a catechol-O-methyl transferase (COMT) inhibitor, e.g., entacapone or tolcapone.
Resumen de: US2025177568A1
This disclosure provides recombinant DNA mol-encoding fusion proteins that are able to regulate expression of alpha-synuclein. Also provided are various compositions comprising the recombinant DNA molecules, as well as associated methods of use. The recombinant DNA molecules and associated methods are useful for the treatment of subjects having disorders caused by excess expression or intracellular accumulation of alpha-synuclein, including Parkinson's disease.
Resumen de: US2025179065A1
Provided herein are compounds that selectively inhibit HDAC6, a protein whose activity is associated with a variety of diseases (e.g., cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HDAC6-related diseases and disorders (e.g., Alzheimer's disease, cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.
Resumen de: US2025179031A1
Described herein are compounds, methods for making such compounds, and the use of such compounds in the treatment of cancer, an inflammatory disease or condition or neurodegenerative diseases, such as Parkinson's disease, Alzheimer's disease, Huntington's disease, and ALS.
Resumen de: EP4563575A1
Disclosed are compounds having general formula I, a method for preparing same, a pharmaceutical composition thereof, and use thereof. Specifically, the present invention provides a compound having a structure represented by general formula I, and a racemate, an R-isomer, an S-isomer and a pharmaceutically acceptable salt thereof, or a mixture thereof. The compound has a good effect on promoting transcription factor EB (TFEB) nuclear translocation and promoting lysosome generation, and can be used for preventing, treating, or assisting in treating various diseases related to lysosome dysfunction and biosynthesis insufficiency, especially neurodegenerative diseases caused by the accumulation of intracerebral pathological proteins (e.g., β-amyloid protein and a-synuclein), such as Alzheimer's disease (AD) and Parkinson's disease (PD).
Resumen de: WO2024026061A1
The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which lowering mutant huntingtin protein ("mHTT") in a subject is of therapeutic benefit, specifically in treating Huntington disease ("HD"). This disclosure also features a composition containing the same as well as methods of using and making the same.
Nº publicación: EP4563154A1 04/06/2025
Solicitante:
H2 GLOBAL GROUP S R O [CZ]
H2 Global Group s.r.o
Resumen de: EP4563154A1
Provided is a drug for treating Alzheimer's disease, the drug enabling retention of cognitive function amelioration and nerve quality improvement for a specific time even after treatment ends. This drug for causal treatment of Alzheimer's disease (disease-modifying drug) contains hydrogen gas as an active ingredient.
BOPI
Sede Electrónica
